Alumis (ALMS) stock exploded higher on Tuesday after the biotech firm reported promising Phase 3 results for envudeucitinib, its candidate treatment for psoriasis.
In the late-stage trial, envudeucitinib helped patients experience symptom improvement that “rank among the strongest reported for an oral therapy,” the company said in its press release.
